<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446093</url>
  </required_header>
  <id_info>
    <org_study_id>PaTK02</org_study_id>
    <nct_id>NCT02446093</nct_id>
  </id_info>
  <brief_title>Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma</brief_title>
  <acronym>PaTK02</acronym>
  <official_title>Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Candel Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Candel Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Gene Mediated Cytotoxic Immunotherapy (GMCI™) in&#xD;
      combination with standard of care chemoradiation and surgery for borderline resectable and&#xD;
      unresectable locally advanced pancreatic cancer in patients who have completed induction&#xD;
      chemotherapy. GMCI kills tumor cells and creates an immune stimulatory environment in the&#xD;
      tumor. Killing tumor cells in an immune stimulatory environment induces the body's immune&#xD;
      system to detect and destroy cancer cells. GMCI has shown synergy with radiation and surgery&#xD;
      without added toxicity. The hypothesis is that GMCI added to standard of care chemoradiation&#xD;
      and surgery after completion of induction chemotherapy will be safe and will improve the&#xD;
      clinical outcome for patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GMCI involves the injection of aglatimagene besadenovec (AdV-tk) into the tumor followed by&#xD;
      oral valacyclovir pills to kill tumor cells and stimulate a cancer vaccine effect. The&#xD;
      current protocol is designed to deliver multiple courses of GMCI in combination with standard&#xD;
      of care chemoradiation and surgery to capitalize on the synergies with the different&#xD;
      treatment modalities.&#xD;
&#xD;
      This protocol includes two phases:&#xD;
&#xD;
        -  Phase 1b - completed.&#xD;
&#xD;
        -  The Phase 2 is a randomized study comparing a test group receiving GMCI added to&#xD;
           chemoradiation and surgery to a control arm receiving chemoradiation followed by&#xD;
           surgery. Participants will be randomized in a 1:1 ratio to GMCI plus standard of care or&#xD;
           standard of care alone. Both arms receive standard of care treatment and evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resection rate</measure>
    <time_frame>4 months</time_frame>
    <description>The percentage of patients receiving an R0 resection will be compared between the two arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety graded by CTC ver4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of adverse events will be compared between the two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of patients alive at 2 years will be compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The PFS curves will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GMCI + chemoradiation + surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemoradiation + surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GMCI (aglatimagene besadenovec + valacyclovir)</intervention_name>
    <description>Three courses of GMCI each involving aglatimagene besadenovec injection into the tumor site followed by 14 days of oral valacyclovir.</description>
    <arm_group_label>Test Arm</arm_group_label>
    <other_name>CAN-2409</other_name>
    <other_name>AdV-tk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Standard of care chemotherapy given with radiation</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
    <other_name>Standard of care radiation given with chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Pancreaticoduodenectomy (Whipple)</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Test Arm</arm_group_label>
    <other_name>Pancreatic cancer resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis of pancreatic adenocarcinoma adequately treated with induction&#xD;
             chemotherapy for at least 2 months such that they are a candidate for localized&#xD;
             therapy with chemoradiation followed by surgery with or without major vascular&#xD;
             resection.&#xD;
&#xD;
          -  Patients must be deemed to be in adequate health to undergo major surgery&#xD;
             (pancreaticoduodenectomy)&#xD;
&#xD;
          -  Tumor accessible for injection that is classified as borderline-resectable or locally&#xD;
             advanced but considered potentially resectable after central review by surgical&#xD;
             investigators (based upon pre-induction chemotherapy imaging). Resection may include&#xD;
             major vascular resection with reconstruction as needed.&#xD;
&#xD;
          -  Age 18-76 years&#xD;
&#xD;
          -  Performance status ECOG 0-1&#xD;
&#xD;
          -  SGOT (AST)&lt;3x upper limit of normal&#xD;
&#xD;
          -  Total bilirubin ≤2mg/dl&#xD;
&#xD;
          -  Creatinine&lt;2mg/dl&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;30ml/m&#xD;
&#xD;
          -  WBC&gt;3000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC)&gt;1500/mm3&#xD;
&#xD;
          -  Platelets&gt;100,000/mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL.&#xD;
&#xD;
          -  Patients must give study specific informed consent prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary hepatic dysfunction including known cirrhosis or active hepatitis. Patients&#xD;
             with biliary obstruction must be stented prior to initiating treatment.&#xD;
&#xD;
          -  Evidence of clinically significant pancreatitis as determined by the investigator&#xD;
&#xD;
          -  Evidence of significant ascites as determined by the investigator&#xD;
&#xD;
          -  Patients on systemic corticosteroids (&gt;10 mg prednisone per day or equivalent) or&#xD;
             other systemic immunosuppressive drugs&#xD;
&#xD;
          -  Known to be HIV+&#xD;
&#xD;
          -  Pregnant or breast-feeding. Female patients of childbearing age must have negative&#xD;
             serum or urine pregnancy test within 1 week of beginning therapy.&#xD;
&#xD;
          -  Other current malignancy (except squamous or basal cell skin cancers)&#xD;
&#xD;
          -  Other serious co-morbid illness or compromised organ function&#xD;
&#xD;
          -  Known sensitivity or allergic reactions to acyclovir or valacyclovir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lee Health/Regional Cancer Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina A Ward</last_name>
      <phone>239-343-9547</phone>
      <email>alina.ward@LeeHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Mark Bloomston, MD</last_name>
      <phone>(239) 333-0995</phone>
      <email>mark.bloomston@21co.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Bloomston, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shona Taylor</last_name>
      <phone>614-685-4337</phone>
      <phone_ext>8230</phone_ext>
      <email>Shona.Taylor@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Dillhoff, MD</last_name>
      <phone>614-293-4583</phone>
      <email>Mary.Dillhoff@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Dillhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sallie Mannen</last_name>
      <phone>434-297-5724</phone>
      <email>sbm8qz@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Tri M Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Uscanga, M.D</last_name>
      <phone>+52 (55)54870900</phone>
      <phone_ext>4401</phone_ext>
      <email>luis.uscangad@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>GMCI</keyword>
  <keyword>AdV-tk</keyword>
  <keyword>aglatimagene besadenovec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

